215,172 Shares in Tango Therapeutics, Inc. $TNGX Bought by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP bought a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 215,172 shares of the company’s stock, valued at approximately $1,906,000. Tango Therapeutics accounts for about 1.4% of Seven Fleet Capital Management LP’s holdings, making the stock its 10th biggest position.

A number of other hedge funds have also recently bought and sold shares of the stock. Legal & General Group Plc grew its position in Tango Therapeutics by 30.7% in the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Tango Therapeutics by 26.7% during the 4th quarter. Russell Investments Group Ltd. now owns 9,794 shares of the company’s stock worth $87,000 after purchasing an additional 2,065 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Tango Therapeutics by 52.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock valued at $58,000 after buying an additional 2,243 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Tango Therapeutics by 12.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,946 shares of the company’s stock valued at $194,000 after buying an additional 2,444 shares during the last quarter. Finally, Barclays PLC raised its position in shares of Tango Therapeutics by 0.7% during the fourth quarter. Barclays PLC now owns 368,187 shares of the company’s stock valued at $3,262,000 after buying an additional 2,507 shares during the last quarter. 78.99% of the stock is owned by institutional investors.

Insider Activity

In other Tango Therapeutics news, insider Adam Crystal sold 38,460 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $25.00, for a total transaction of $961,500.00. Following the transaction, the insider owned 112,622 shares in the company, valued at approximately $2,815,550. This trade represents a 25.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders sold 131,460 shares of company stock valued at $2,965,920. 6.50% of the stock is owned by company insiders.

Tango Therapeutics Stock Performance

Tango Therapeutics stock opened at $27.97 on Friday. The business’s fifty day moving average is $24.30 and its two-hundred day moving average is $16.99. The firm has a market cap of $4.05 billion, a P/E ratio of -33.70 and a beta of 1.19. Tango Therapeutics, Inc. has a 52 week low of $4.60 and a 52 week high of $34.39.

Tango Therapeutics (NASDAQ:TNGX) last announced its earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.32). Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 41.54%. On average, equities research analysts predict that Tango Therapeutics, Inc. will post -1.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on TNGX shares. Wedbush lifted their target price on Tango Therapeutics from $19.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Citigroup reaffirmed a “buy” rating on shares of Tango Therapeutics in a report on Monday, April 27th. Leerink Partners raised their price objective on Tango Therapeutics from $55.00 to $69.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Mizuho set a $36.00 price objective on Tango Therapeutics in a research report on Monday, June 8th. Finally, Stifel Nicolaus lifted their price objective on Tango Therapeutics from $24.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $38.42.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.